The presence of D2R in all pituitary cell types, data from in vitro studies, and clinical data suggest DA may also be an effective primary or second-line treatment for some patients with CD, and as second-line therapy in selected patients with persistent/recurrent acromegaly or NFPT. Here, DRD2 is linked to acromegaly.